Online inquiry

IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12945MR)

This product GTTS-WQ12945MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MUC1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12945MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7263MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FP3 protein
GTTS-WQ13015MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ7945MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ4199MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB019
GTTS-WQ9476MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ13019MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ9917MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ5101MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Campath-1H
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW